Blue Bees Therapeutics develops immunomodulatory proteins with therapeutic potential to fight cancer
Blue Bees Therapeutics is a biotechnology company founded in 2022, dedicated to the development of first-in-class immunotherapies for the treatment of cancers, based on a breakthrough technology discovered by the team led by Dr Michel Léonetti, within the Department of Pharmacology and Immunoanalysis from CEA Paris-Saclay.
This technology allows to generate unique bi-specific receptor/ co-receptor engaging immunomodulatory antibodies.
BB101 lead product stimulates anti-tumor immune response targeting FcgR coupled with heparan sulphate proteoglycans (HSPG).
Blue Bees Therapeutics has obtained an exclusive worldwide license from the CEA
and is supported by SATT Paris-Saclay, in order to validate its first drug candidate, BB10x.
Antibody-based immunotherapeutic drugs have considerable potential in oncology, as evidenced by the spectacular successes achieved in the treatment of certain cancers (melanoma, lung, etc.), posting a turnover of 47 billion dollars in 2024.
However, the treatments currently available on the market have the disadvantage of only working for 10 to 60% of patients and are not without side effects. These limits have paved the way for the definition of new therapeutic immunomodulators proposed by Blue Bees Therapeutics.